Table 3 Feasibility outcomes. Values are n (%) unless otherwise noted
| Â | High Load | Low Load | ||
|---|---|---|---|---|
| Â | with High TUT | with Low TUT | with High TUT | with Low TUT |
Session time duration in minutesa | 43.4 (12.2) | 39.0 (6.1) | 53.0 (7.3) | 37.1 (7.0) |
Adherenceb | ||||
 Number of zoom sessions completed / 12 | 11 (92) | 9 (71) | 11 (92) | 10 (79) |
 Number of home sessions completed / 36 | 21 (58) | 18 (49) | 21 (58) | 25 (68) |
Fidelity of exercise dose parameters in seated | ||||
 Time-under-tension | 5 (42) | 5 (42) | 6 (50) | 7 (58) |
 Volume | 7 (58) | 8 (67) | 8 (67) | 10 (83) |
 Load intensity | 6 (50) | 1 (8) | 8 (67) | 8 (67) |
Fidelity of exercise dose parameters in standing | ||||
 Time-under-tension | 5 (42) | 3 (25) | 6 (50) | 6 (50) |
 Volume | 7 (58) | 7 (58) | 8 (67) | 7 (58) |
 Load intensity | 5 (42) | 4 (33) | 9 (75) | 7 (58) |
No. of participants who reporting adverse event | 8 (67) | 8 (67) | 8 (67) | 6 (50) |
Severity of adverse events c | ||||
 Mild | 4 (33) | 6 (50) | 8 (67) | 3 (25) |
 Moderate | 3 (25) | 2 (17) | 0 | 3 (25) |
 Severe | 1 (8) | 0 | 0 | 0 |
Achilles related adverse events | 3 (25) | 4 (33) | 4 (33) | 4 (33) |
Severity of Achilles related adverse events | ||||
 Mild | 3 (25) | 4 (33) | 4 (33) | 3 (25) |
 Moderate | 0 | 0 | 0 | 0 |
 Severe | 0 | 0 | 0 | 0 |
No. of participants who used co-interventions | 3 (25) | 2 (17) | 2 (17) | 4 (33) |
No. of participants using paracetamol | 4 (33) | 5 (42) | 4 (33) | 6 (50) |
Total paracetamol tablets used d | 16 (33) | 31 (33) | 33 (25) | 17 (25) |